Display options
Cite
Gomzikova MO, Zhuravleva MN, Miftakhova RR, et al. Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells. Oncotarget. 2017;8(41):70496-70507doi: 10.18632/oncotarget.19723.
Gomzikova, M. O., Zhuravleva, M. N., Miftakhova, R. R., Arkhipova, S. S., Evtugin, V. G., Khaiboullina, S. F., Kiyasov, A. P., Persson, J. L., Mongan, N. P., Pestell, R. G., & Rizvanov, A. A. (2017). Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells. Oncotarget, 8(41), 70496-70507. https://doi.org/10.18632/oncotarget.19723
Gomzikova, Marina O, et al. "Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells." Oncotarget vol. 8,41 (2017): 70496-70507. doi: https://doi.org/10.18632/oncotarget.19723
Gomzikova MO, Zhuravleva MN, Miftakhova RR, Arkhipova SS, Evtugin VG, Khaiboullina SF, Kiyasov AP, Persson JL, Mongan NP, Pestell RG, Rizvanov AA. Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells. Oncotarget. 2017 Jul 31;8(41):70496-70507. doi: 10.18632/oncotarget.19723. eCollection 2017 Sep 19. PMID: 29050297; PMCID: PMC5642572.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 31;8(41):70496-70507. doi: 10.18632/oncotarget.19723. eCollection 2017 Sep 19.

Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells.

Oncotarget

Marina O Gomzikova, Margarita N Zhuravleva, Regina R Miftakhova, Svetlana S Arkhipova, Vladimir G Evtugin, Svetlana F Khaiboullina, Andrey P Kiyasov, Jenny L Persson, Nigel P Mongan, Richard G Pestell, Albert A Rizvanov

Affiliations

  1. Kazan Federal University, Kazan, 420008, Russia.
  2. Department of Microbiology and Immunology, University of Nevada, Reno, Nevada, 89557, USA.
  3. Department of Translational Medicine, Lund University, 205 02 Malmö, and Department of Molecular Biology, 901 87 Umeå, Umeå University.
  4. Cancer Biology and Translational Research, School of Veterinary Medicine and Science, University of Nottingham, LE12 5RD, UK.
  5. Department of Pharmacology, Weill Cornell Medicine, 1300 York Ave., New York, NY, 10065, USA.
  6. Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, 100 East Lancaster Avenue, Suite, 222, Wynnewood, PA 19096. USA.
  7. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 637551, Singapore.

PMID: 29050297 PMCID: PMC5642572 DOI: 10.18632/oncotarget.19723

Abstract

Naturally occurring extracellular vesicles (EVs) play essential roles in intracellular communication and delivery of bioactive molecules. Therefore it has been suggested that EVs could be used for delivery of therapeutics. However, to date the therapeutic application of EVs has been limited by number of factors, including limited yield and full understanding of their biological activities. To address these issues, we analyzed the morphology, molecular composition, fusion capacity and biological activity of Cytochalasin B-induced membrane vesicles (CIMVs). The size of these vesicles was comparable to that of naturally occurring EVs. In addition, we have shown that CIMVs from human SH-SY5Y cells contain elevated levels of VEGF as compared to the parental cells, and stimulate angiogenesis

Keywords: angiogenesis; cell-free therapy; cytochalasin B-induced membrane vesicles; extracellular vesicles; membrane vesicles

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that there is no conflicts of interests regarding the publication of this article.

References

  1. Cell. 1980 Jun;20(2):329-41 - PubMed
  2. Front Immunol. 2014 Dec 03;5:608 - PubMed
  3. J Extracell Vesicles. 2013 May 27;2:null - PubMed
  4. Stem Cell Res. 2010 May;4(3):214-22 - PubMed
  5. J Immunol Methods. 2001 Jan 1;247(1-2):163-74 - PubMed
  6. Expert Rev Proteomics. 2009 Jun;6(3):267-83 - PubMed
  7. J Cell Biol. 2013 Feb 18;200(4):373-83 - PubMed
  8. J Neurooncol. 2013 May;113(1):1-11 - PubMed
  9. Regen Med. 2011 Jan;6(1):45-52 - PubMed
  10. J Extracell Vesicles. 2014 Aug 04;3:null - PubMed
  11. Mol Brain. 2016 Jun 07;9(1):63 - PubMed
  12. Kidney Int. 2012 Aug;82(4):412-27 - PubMed
  13. Nephrol Dial Transplant. 2012 Aug;27(8):3037-42 - PubMed
  14. Stem Cells Transl Med. 2016 Apr;5(4):440-50 - PubMed
  15. Int J Cancer. 2015 Oct 1;137(7):1630-42 - PubMed
  16. Int J Stem Cells. 2014 Nov;7(2):158-61 - PubMed
  17. PLoS One. 2014 Oct 17;9(10):e110314 - PubMed
  18. Tumour Biol. 2016 Sep;37(9):12743-12753 - PubMed
  19. J Cell Biol. 1986 Jul;103(1):171-87 - PubMed
  20. J Exp Med. 1996 Mar 1;183(3):1161-72 - PubMed
  21. Nano Lett. 2011 May 11;11(5):2152-6 - PubMed
  22. Cancer Res. 1978 Nov;38(11 Pt 1):3751-7 - PubMed
  23. J Cereb Blood Flow Metab. 2013 Nov;33(11):1711-5 - PubMed
  24. PLoS One. 2012;7(3):e34045 - PubMed
  25. J Clin Invest. 2005 Jul;115(7):1743-55 - PubMed
  26. Neurosurgery. 2011 Mar;68(3):588-600 - PubMed
  27. Stem Cell Res. 2013 May;10 (3):301-12 - PubMed
  28. J Cell Mol Med. 2010 Jun;14(6B):1605-18 - PubMed
  29. J Am Chem Soc. 2005 Mar 9;127(9):2908-12 - PubMed
  30. FASEB J. 2006 Apr;20(6):661-9 - PubMed
  31. J Am Soc Nephrol. 2009 May;20(5):1053-67 - PubMed
  32. J Cell Mol Med. 2012 Jul;16(7):1508-21 - PubMed
  33. J Oncol. 2012;2012:782020 - PubMed
  34. Eur J Pharm Biopharm. 2010 Oct;76(2):253-9 - PubMed
  35. Proteomics. 2013 May;13(10-11):1554-71 - PubMed
  36. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4852-7 - PubMed
  37. Endocrine. 2013 Aug;44(1):11-9 - PubMed
  38. J Mol Cell Cardiol. 2011 Feb;50(2):280-9 - PubMed
  39. Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H886-93 - PubMed
  40. Respiration. 2015 ;90(6):481-92 - PubMed

Publication Types